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THE ‘SMART’ AMINE DONORS O-XYLYLENEDIAMINE AND 
CADAVERINE WERE EMPLOYED FOR THE RAPID SCREENING OF 
A LARGE KETONE LIBRARY AND SUBSEQUENT PREPARATIVE-
SCALE SYNTHESIS OF SELECTED COMPOUNDS USING THE 
COMMERCIALLY AVAILABLE AMINE TRANSAMINASE, ATA256. 
THE METHODOLOGY ENABLES BOTH SCREENING AND 
PREPARATIVE-SCALE BIOTRANSFORMATIONS TO BE 
PERFORMED WITH A SINGLE ENZYME AND SIMPLIFIES THE 
GENERATION OF SP3-RICH SMALL MOLECULE LIBRARIES. 
Chiral amines are ubiquitous in pharmaceutical drugs, 
bioactive natural products and privileged scaffolds.[1-2] 
Asymmetric introduction of amines into small molecule 
libraries represents an attractive way of increasing their 
complexity.[3-5] It has been demonstrated that ‘sp3-rich’ 
compounds possessing one or more stereocentres have 
favourable properties for drug discovery processes.[6-7] In 
order to produce diverse libraries of optically pure chiral 
amines, robust strategies for their preparation must be 
developed.  
 Current methods for asymmetric amine synthesis 
typically rely on chiral auxiliaries or precious metal catalysts 
and often require harsh reaction conditions (high 
temperatures, pressures etc).[8] The application of enzymes 
for their synthesis represents a sustainable alternative, as 
biotransformations are normally carried out under mild 
conditions and often display superior regio- and 
stereoselectivity to the traditional chemical approaches.  
 Amine transaminase (ATA) enzymes have emerged as 
powerful catalysts for the production of chiral amines, with 
many impressive examples of their application present in the 
scientific literature.[9-12] ATAs are pyridoxal-5-phosphate-
dependent (PLP-dependent) and can catalyse the reversible 
formation of chiral amines from pro-chiral ketones using a 
suitable sacrificial amine donor. The reversibility of this 
transformation means that efficient methods to displace the 
often challenging reaction equilibrium are necessary to 
achieve high conversion of substrate to product.  
 Commonly employed strategies include the use of a large 
excess of amine donor coupled with in situ co-product 
removal or enzymatic degradation of the reaction by-
product.[9,10, 13-16] We previously demonstrated that ortho-
xylyenediamine can be used to effectively displace the 
reaction equilibrium of some of the most challenging 
substrates, using near stoichiometric equivalents of the 
‘smart’ diamine donor.[17] Additionally, the co-products 
formed upon transamination with this donor are highly 
coloured, suggesting that it could be employed for high-
throughput screening of both large enzyme and ketone 
libraries. We have also extended this methodology to other 
low-cost diamine donors, including cadaverine.[18] The 
efficient conversion achieved using these diamines can be 
attributed to the spontaneous cyclisation and subsequent 
oligimerization/polymerization of the co-products, which 
effectively displaces the reaction equilibrium. This 
methodology has since been shown to be effective with other 
ATAs and importantly, with other low-cost, bulk diamine 
donors.[19] The development of biocatalytic approaches for 
the synthesis of chiral amines that exploit ‘smart’ low-cost 
diamine donors, in place of IPA coupled with complex co-
product removal, is of great interest. 
  We have now demonstrated that o-xylylenediamine can 
be employed for the rapid screening of a large library of 
commercially available ketones and aldehydes, enabling 
expedient identification of transaminase substrates. Based 
on this high-throughput screening data, a selection of 
ketones were converted to the corresponding chiral primary 
amines on a preparative-scale, using cadaverine. The 
approach demonstrates that these two smart donors can be 
used in combination for efficient screening and subsequent 
scale-up, using lower cost diamine donors.    
 A library containing 400 ketones/aldehydes was supplied 
by our industrial partner, Key Organics. Compounds within 
this library were structurally diverse and many of the 
corresponding amines were of commercial interest. 
Screening was conducted in 96-well plates and results 
analysed after 1 and 24 hours (figure 1). The formation of a 
dark precipitate in the wells enabled qualitative identification  
of enzyme substrates. 
Figure 1. Representative assay plate showing the screening of a ketone 
library using o-xylylenediamine. Wells containing dark precipitate indicate 
ATA activity. 
 
Analysis of the assay data (figure. 2) revealed that 
smaller, low molecular weight compounds (<225 Da) are 
readily accepted by commercially available ATA 256; an 
enzyme developed by Codexis.[20]  This data demonstrates 
that in a library of diverse compounds, larger molecules are 
less likely to be accepted. However, molecular weight and 
size are not the only important factors and electronic effects, 
as well as the nature of the substituents on the ketone are 
also extremely relevant. As expected, the data showed that 
alpha aryl-substituted methyl ketones were less amenable to 
transamination compared to those with an alkyl substituent 
(figure. 3). Cyclic ketones were well tolerated whereas α,β 
unsaturated ketones were poorer substrates.[21] 
Several ketones were then selected for quantitative 
analysis (Figure 3) based on our interest in producing the 
corresponding chiral amines on a preparative scale. The 
amines selected were either not commercially available, 
were extremely expensive or were difficult to produce using 
traditional chemical approaches. Analytical scale reactions 
  
 
 
 
 
Figure 2. Characterisation of ketones used in the library screening and a 
plot of their molecular weight vs volume.[22, 22] 
 
were performed using our recently reported diamine donor 
cadaverine[17] and compared to transformations using 
isopropylamine (the current industry standard amine donor).  
As expected, reactions employing cadaverine outperformed 
isopropylamine in almost all cases (figure 3). Using 3 
equivalents of cadaverine was sufficient to achieve a 98% 
conversion of challenging ketone 1 to the corresponding 
amine. A conversion of only 70% was achieved using IPA at 
the same concentration. The diamine donor also significantly 
outperformed IPA in the biotransformations involving the low 
molecular weight ketones, 5-8. These ketones (5-8) have 
particularly low boiling points and therefore using high 
concentrations of IPA in combination with in situ acetone co-
product removal is likely to be challenging, as the volatile 
ketone starting material would also be evaporated under 
these conditions. For this reason, we choose to demonstrate 
the utility of the ‘smart’ amine donor, cadaverine, and by 
extension similar low-cost diamine donors, by preforming 
reparative-scale biotransformations with ketones 1 and 12 
and volatile ketones 6-8. 
Initial studies showed that using DMSO as a co-solvent was 
likely to complicate chromatographic purification when 
reactions were performed on a preparative scale. A variety 
of other co-solvents were screened and biotransformations 
containing methanol and ethanol reached similar 
conversions to those with DMSO, indicating that these were 
good alternative solvents. Acetone was the only co-solvent 
that gave poor conversions, with some of the 
biotransformations being completely inhibited (see 
supplementary data).  
  
 
 
 
 
 
 
 
 
 
 
Figure 3: Analytical scale biotransformations with a selection of ketone 
substrates 1-13, utilising either 1 or 3 equivalents of the amine donors, 
cadaverine or IPA. Conversions of compounds 1-13 (20 mM) to the 
corresponding amine were carried out using ATA256 (2.5 mg/ml), PLP (1 
mM) and cadaverine or IPA (20mM). Conversions are an average of three 
replicates.   
 
  
Preparative biotransformations were carried out with 
ketones 6-8 in HEPES buffer at pH 10.9, using DMSO as a 
co-solvent and were purified by distillation (see ESI for 
further details). All reactions proceeded with excellent ee 
(>99%), which was established by the synthesis and NMR 
analysis of the corresponding Mosher’s acid chlorides (see 
supporting information for details).[24] Compounds 1 and 12 
were extracted and purified via column chromatography in 
70% and 39% yield respectively. In all cases, the compounds 
were of sufficient purity for commercialisation.  
 The synthesis and application of ‘sp3-rich’ fragments 
remains highly important in modern drug-discovery 
processes and it is expected that this methodology can 
provide synthetic and medicinal chemists with a facile route 
for the synthesis of chiral amine fragments. There is 
increasing interest from industry in the development of 
sustainable, bio-derived chiral molecules and the use of 
commercially available enzymes and mild reaction 
conditions make this approach attractive for accessing these 
synthetically challenging compounds. Work is on-going to 
directly evolve new enzymes that possess a broader 
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substrate scope and that can utilise ‘smart’ amine donors. 
This will expand the use of the biocatalytic toolbox in modern 
synthesis. 
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